Incyte Corp to Discuss Opzelura In Vitiligo FDA Approval Call Summary - Thomson StreetEvents

Incyte Corp to Discuss Opzelura In Vitiligo FDA Approval Call Summary

Incyte Corp to Discuss Opzelura In Vitiligo FDA Approval Call Summary - Thomson StreetEvents
Incyte Corp to Discuss Opzelura In Vitiligo FDA Approval Call Summary
Published Jul 19, 2022
15 pages (8201 words) — Published Jul 19, 2022
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of INCY.OQ conference call or presentation 19-Jul-22 12:00pm GMT

  
Brief Excerpt:

...INCY announced the FDA approval of Opzelura for the treatment of adolescent and adults living with nonsegmental vitiligo....

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
Incyte Corp
Ticker
INCY.OQ
Time
12:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

Incyte Corp Q3 2022 Earnings Call Summary – 2022-11-01 – US$ 54.00 – Edited Brief of INCY.OQ earnings conference call or presentation 1-Nov-22 12:00pm GMT

Incyte Corp at Morgan Stanley Global Healthcare Conference Transcript – 2022-09-12 – US$ 54.00 – Edited Transcript of INCY.OQ presentation 12-Sep-22 4:30pm GMT

Incyte Corp Q2 2022 Earnings Call Summary – 2022-08-02 – US$ 54.00 – Edited Brief of INCY.OQ earnings conference call or presentation 2-Aug-22 12:00pm GMT

Incyte Corp Q2 2022 Earnings Call Transcript – 2022-08-02 – US$ 54.00 – Edited Transcript of INCY.OQ earnings conference call or presentation 2-Aug-22 12:00pm GMT

Incyte Corp to Discuss Opzelura In Vitiligo FDA Approval Call Transcript – 2022-07-19 – US$ 54.00 – Edited Transcript of INCY.OQ conference call or presentation 19-Jul-22 12:00pm GMT

Incyte Corp at Goldman Sachs Global Healthcare Conference Transcript – 2022-06-14 – US$ 54.00 – Edited Transcript of INCY.OQ presentation 14-Jun-22 3:00pm GMT

Incyte Corp at RBC Capital Markets Global Healthcare Conference Transcript – 2022-05-17 – US$ 54.00 – Edited Transcript of INCY.OQ presentation 17-May-22 2:30pm GMT

Incyte Corp Q1 2022 Earnings Call Summary – 2022-05-03 – US$ 54.00 – Edited Brief of INCY.OQ earnings conference call or presentation 3-May-22 12:00pm GMT

Incyte Corp Q1 2022 Earnings Call Transcript – 2022-05-03 – US$ 54.00 – Edited Transcript of INCY.OQ earnings conference call or presentation 3-May-22 12:00pm GMT

Incyte Corp at Cowen Health Care Conference (Virtual) Transcript – 2022-03-07 – US$ 54.00 – Edited Transcript of INCY.OQ presentation 7-Mar-22 2:50pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Incyte Corp to Discuss Opzelura In Vitiligo FDA Approval Call Summary" Jul 19, 2022. Alacra Store. May 15, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Incyte-Corp-to-Discuss-Opzelura-In-Vitiligo-FDA-Approval-Call-B15268818>
  
APA:
Thomson StreetEvents. (2022). Incyte Corp to Discuss Opzelura In Vitiligo FDA Approval Call Summary Jul 19, 2022. New York, NY: Alacra Store. Retrieved May 15, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Incyte-Corp-to-Discuss-Opzelura-In-Vitiligo-FDA-Approval-Call-B15268818>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.